Endoscopic eradication therapy for Barrett's esophagus: Adverse outcomes, patient values, and cost-effectiveness

Swarup Kumar, Prasad G Iyer

Research output: Contribution to journalArticle

Abstract

Endoscopic therapy for Barrett's esophagus (BE) aims to replace dysplastic BE epithelium with neosquamous epithelium to prevent and reduce the risk of progression to esophageal adenocarcinoma (EAC) and treat early-stage EAC. Various modalities of endotherapy of dysplastic BE are described. Although endoscopic therapy is safe and effective in treating subjects with intramucosal carcinoma (IMCa), high-grade dysplasia (HGD), and confirmed low-grade dysplasia (LGD), challenges to successful treatment are being recognized. Though adverse outcomes of endotherapy such as bleeding, perforation, pain, and stricture formation are observed, they are not common and can usually be treated medically or endoscopically. Patient values and preferences toward endoscopic therapy and the cost-effectiveness of these endoscopic approaches also have crucial implications for the selection of appropriate treatment and subsequent outcomes in patients with BE.

Original languageEnglish (US)
JournalTechniques in Gastrointestinal Endoscopy
DOIs
StateAccepted/In press - Jan 1 2018

Fingerprint

Barrett Esophagus
Cost-Benefit Analysis
Adenocarcinoma
Therapeutics
Patient Preference
Pathologic Constriction
Epithelium
Hemorrhage
Carcinoma
Pain

Keywords

  • Adverse outcomes
  • Barrett's esophagus
  • Cost-effectiveness
  • Endoscopic therapy
  • Patient values

ASJC Scopus subject areas

  • Radiology Nuclear Medicine and imaging
  • Gastroenterology

Cite this

@article{6b76200325104207916db3f383fb4df4,
title = "Endoscopic eradication therapy for Barrett's esophagus: Adverse outcomes, patient values, and cost-effectiveness",
abstract = "Endoscopic therapy for Barrett's esophagus (BE) aims to replace dysplastic BE epithelium with neosquamous epithelium to prevent and reduce the risk of progression to esophageal adenocarcinoma (EAC) and treat early-stage EAC. Various modalities of endotherapy of dysplastic BE are described. Although endoscopic therapy is safe and effective in treating subjects with intramucosal carcinoma (IMCa), high-grade dysplasia (HGD), and confirmed low-grade dysplasia (LGD), challenges to successful treatment are being recognized. Though adverse outcomes of endotherapy such as bleeding, perforation, pain, and stricture formation are observed, they are not common and can usually be treated medically or endoscopically. Patient values and preferences toward endoscopic therapy and the cost-effectiveness of these endoscopic approaches also have crucial implications for the selection of appropriate treatment and subsequent outcomes in patients with BE.",
keywords = "Adverse outcomes, Barrett's esophagus, Cost-effectiveness, Endoscopic therapy, Patient values",
author = "Swarup Kumar and Iyer, {Prasad G}",
year = "2018",
month = "1",
day = "1",
doi = "10.1016/j.tgie.2018.02.002",
language = "English (US)",
journal = "Techniques in Gastrointestinal Endoscopy",
issn = "1096-2883",
publisher = "W.B. Saunders Ltd",

}

TY - JOUR

T1 - Endoscopic eradication therapy for Barrett's esophagus

T2 - Adverse outcomes, patient values, and cost-effectiveness

AU - Kumar, Swarup

AU - Iyer, Prasad G

PY - 2018/1/1

Y1 - 2018/1/1

N2 - Endoscopic therapy for Barrett's esophagus (BE) aims to replace dysplastic BE epithelium with neosquamous epithelium to prevent and reduce the risk of progression to esophageal adenocarcinoma (EAC) and treat early-stage EAC. Various modalities of endotherapy of dysplastic BE are described. Although endoscopic therapy is safe and effective in treating subjects with intramucosal carcinoma (IMCa), high-grade dysplasia (HGD), and confirmed low-grade dysplasia (LGD), challenges to successful treatment are being recognized. Though adverse outcomes of endotherapy such as bleeding, perforation, pain, and stricture formation are observed, they are not common and can usually be treated medically or endoscopically. Patient values and preferences toward endoscopic therapy and the cost-effectiveness of these endoscopic approaches also have crucial implications for the selection of appropriate treatment and subsequent outcomes in patients with BE.

AB - Endoscopic therapy for Barrett's esophagus (BE) aims to replace dysplastic BE epithelium with neosquamous epithelium to prevent and reduce the risk of progression to esophageal adenocarcinoma (EAC) and treat early-stage EAC. Various modalities of endotherapy of dysplastic BE are described. Although endoscopic therapy is safe and effective in treating subjects with intramucosal carcinoma (IMCa), high-grade dysplasia (HGD), and confirmed low-grade dysplasia (LGD), challenges to successful treatment are being recognized. Though adverse outcomes of endotherapy such as bleeding, perforation, pain, and stricture formation are observed, they are not common and can usually be treated medically or endoscopically. Patient values and preferences toward endoscopic therapy and the cost-effectiveness of these endoscopic approaches also have crucial implications for the selection of appropriate treatment and subsequent outcomes in patients with BE.

KW - Adverse outcomes

KW - Barrett's esophagus

KW - Cost-effectiveness

KW - Endoscopic therapy

KW - Patient values

UR - http://www.scopus.com/inward/record.url?scp=85042915636&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85042915636&partnerID=8YFLogxK

U2 - 10.1016/j.tgie.2018.02.002

DO - 10.1016/j.tgie.2018.02.002

M3 - Article

AN - SCOPUS:85042915636

JO - Techniques in Gastrointestinal Endoscopy

JF - Techniques in Gastrointestinal Endoscopy

SN - 1096-2883

ER -